Schmidt Peter M
CSIRO Molecular & Health Technologies, 343 Royal Parade, Parkville, VIC, 3052, Australia.
Handb Exp Pharmacol. 2009(191):195-228. doi: 10.1007/978-3-540-68964-5_10.
Cyclic guanosine monophosphate (cGMP), generated via the guanylate cyclase (GC)-catalyzed conversion from GTP, is unequivocally recognized as crucial second messenger, intimately involved in the regulation of a broad range of physiological processes such as long term potentiation, blood pressure regulation, or platelet aggregation (for review: Hobbs 2000). Since its first identification in rat urine by Ashman and co-workers (1963), various approaches have been conceived and established to quantify cGMP in biological samples, or to detect cGMP as the reaction product of enzymatic assays, allowing the determination of kinetic parameters. These approaches have evolved from laborious handling of small numbers of samples with average sensitivity to highly developed biochemical detection assays allowing the processing of very large numbers of samples. The present article focuses upon the history of biochemical cGMP detection from the pioneering work of the early years to the actual state-of-the-art approaches for the detection of this important biological messenger.
环磷酸鸟苷(cGMP)由鸟苷酸环化酶(GC)催化GTP转化生成,它被明确认为是至关重要的第二信使,密切参与多种生理过程的调节,如长时程增强、血压调节或血小板聚集(综述:Hobbs 2000)。自1963年Ashman及其同事首次在大鼠尿液中鉴定出cGMP以来,人们构思并建立了各种方法来定量生物样品中的cGMP,或检测cGMP作为酶促反应的产物,从而确定动力学参数。这些方法已经从对少量样品进行繁琐处理且灵敏度一般,发展到高度发达的生化检测方法,能够处理大量样品。本文重点介绍生化cGMP检测的历史,从早期的开创性工作到检测这种重要生物信使的当前先进方法。